IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas ICH 20089, Rozzano, Milan, Italy.
Curr Drug Targets. 2013 Nov;14(12):1444-52. doi: 10.2174/13894501113149990170.
Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases. The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
在理解炎症性肠病（IBD）的分子机制方面已经做了很多工作。IL-13 已成为一种在溃疡性结肠炎（UC）和瘘管性克罗恩病（CD）中有效的重要细胞因子。IL-13 是一种辅助性 T 细胞 2 型细胞因子，具有多种作用，参与寄生虫排出、哮喘病理生理学、癌症的自然史和其他人类病理学。因此，人们对抑制其功能作为这些疾病的治疗干预措施产生了浓厚的兴趣。IL-13 的多功能特性，特别是其在 CD 和 UC 中的作用，以及目前正在开发的抑制 IL-13 信号通路的药物，都进行了综述。抗 IL-13 药物似乎是未来管理 IBD 和其他人类疾病的有前途的治疗策略。
